期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性粒细胞白血病治疗中克服伊马替尼耐药的新策略 被引量：1

New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia
原文传递
导出
摘要 慢性髓系白血病（chronic myelogenous leukemia，CML）是以恶性髓系祖细胞克隆性增殖为特征。95％CML患者的造血干细胞中存在BCR-ABL融合基因，它是由9号和22号染色体相互易位而形成t（9；22）（q34；q11），细胞遗传学上可见缩短的22号染色体。BCR-ABL融合基因编码的BCR-ABL蛋白为胞浆蛋白，具有持续活化的酪氨酸激酶活性，可导致自身酪氨酸残基磷酸化及许多重要的底物蛋白磷酸化，从而激活多条信号传导途径，使细胞转化、增殖、分化和凋亡受阻。
作者 刘鹤 陈晓光
机构地区 中国医学科学院中国协和医科大学药物研究所
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2006年第8期561-563,共3页 Chinese Journal of Oncology
关键词 慢性粒细胞白血病 伊马替尼 药物耐受性 Chronic myelocytic leukemia Imatinib mesylate Drug resistance
分类号 R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Heisterkamp N, Stephenson JR, Groffen J, et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature, 1983, 306 : 239-242.
  • 2Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 1996, 2: 561-566.
  • 3Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med, 2001, 344: 1038-1042.
  • 4Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 2001,293: 876-880.
  • 5Gambacorti-Passerini C, Barni R, le Coutre P, et al. Role of alphal acid glycoprotein in the in vivo resistance of human BCR-ABL( + )leukemic cells to the abl inhibitor STI571. J Nail Cancer Inst, 2000,92 : 1641-1650.
  • 6Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood, 2003, 101 : 473-475.
  • 7Schindler T, Bommann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science, 2000,289 : 1938-1942.
  • 8Gumireddy K, Baker SJ, Cosenza SC, et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA, 2005, 102 : 1992-1997.
  • 9Yu C, Krystal G, Varticovksi L, et al. Pharmacologic mitogenactivated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res, 2002, 62:188-199.
  • 10Sattler M, Salgia R, Okuda K, et al. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL,p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3 'kinase pathway. Oncogene, 1996, 12: 839-846.

同被引文献11

  • 1张燕捷,吴叔明,李恩灵,朱红音,沈冠凤,罗鸿予,萧树东.非甾体消炎药诱导胃癌细胞凋亡及其机制的研究[J].中国癌症杂志,2004,14(5):432-436. 被引量：5
  • 2陈朝飞,房静远,孙丹凤,翁玉蓉,李恩灵,朱红音,顾伟齐.丝裂原激活蛋白激酶阻断剂与DNA甲基化酶抑制剂对人结肠癌细胞的协同影响[J].中华消化杂志,2006,26(2):87-91. 被引量：5
  • 3陈朝飞,房静远,翁玉蓉,孙丹凤,王霞,陆嵘.蛋白激酶C-δ阻断剂Rottlerin对人结肠癌细胞的影响及其机理[J].中华肿瘤杂志,2006,28(8):564-567. 被引量：3
  • 4Rubio-Viqueira B, Hidalgo M. Targeting mTOR for cancer treatment. Curt Opin Investig Drugs, 2006, 7:501-512.
  • 5Fang JY, Mikovits JA, Bagni R, et al. Infection of lymphoid cells by integration-defective human immunodeficiency rims type 1 Increases de novo methylation. J Virol, 2001,75: 9753-9761.
  • 6Wullschleger S, Loewith B, Hall MN. TOB signaling in growth and metabolism. Cell, 2006, 124: 471-484.
  • 7Petroulakis E, Mamane Y, Le Bacquer O, et al. mTOR signaling:implications for cancer and anticancer therapy. Br J Cancer, 2006, 94 : 195-199.
  • 8Fang JY, Richardson BC. The MAPK signaling pathways and colorectal cancer. Lancet Oncol, 2005,6:322-327.
  • 9Fang P, Hwa V, Rosenfeld RG. Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway. Exp Cell Res, 2006, 312 : 1229-1239.
  • 10Fukazawa H, Noguchi K, Murakami Y, et al. Mitogen-activated protein,/extracellular signal-regulated kinase kinase ( MEK )inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase ( ERK ) pathway. Mol Cancer Ther, 2002, 1:303-309.

引证文献1

二级引证文献7

中华肿瘤杂志
2006年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部